Access the transcript here
HOUSTON, Oct. 17,
2024 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage
pharmaceutical company with a broad portfolio of drug candidates
targeting hard-to-treat tumors and viruses, today announced the
transcript from its recently hosted Virtual Acute Myeloid Leukemia
KOL event is now available. The transcript is accessible under the
Virtual AML KOL event on the Event page under the Investors section
of the Company's website (moleculin.com) and on the SEC Filings
page.
For the event, Walter Klemp,
Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of
Moleculin were joined by key opinion leaders: Michael Andreef, MD, PhD, Professor of Medicine,
Department of Stem Cell Transplantation, Division of Cancer
Medicine, The University of Texas MD
Anderson Cancer Center; Dr. Giovanni
Martinelli, Associate Professor; Department of Medical and
Surgical Sciences, Bologna University; and Mohamad Cherry, MD, Medical Director of
Hematology at Atlantic Health System. The event included an
overview of Annamycin; the use of anthracyclines, how Annamycin
could significantly change the AML treatment landscape, and the
Company's recently announced global Phase 3 pivotal trial for the
treatment of AML patients who are refractory to or relapsed after
induction therapy (R/R AML) (the "MIRACLE" trial).
"We are incredibly grateful to the esteemed AML thought leaders
who took time out of their busy schedules to share their valuable
insight at our recent event. Their continued enthusiasm and
support for the potential of Annamycin bolsters our confidence as
we advance our development program and provides a valuable
perspective from practicing physicians who are meeting with the AML
patient population on a daily basis. With the growing body of
positive preliminary data demonstrated by Annamycin, we believe we
have the potential to address the significant unmet need for safe
and effective therapies for R/R AML," commented Walter Klemp, Chairman and Chief Executive
Officer of Moleculin.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage
pharmaceutical company advancing a pipeline of therapeutic
candidates addressing hard-to-treat tumors and viruses. The
Company's lead program, Annamycin, is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms and
to eliminate the cardiotoxicity common with currently prescribed
anthracyclines. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin
R/R AML AnnAraC Clinical Evaluation)
Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating
Annamycin in combination with cytarabine, together referred to as
AnnAraC, for the treatment of relapsed or refractory acute myeloid
leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the
Company believes it has substantially de-risked the development
pathway towards a potential approval for Annamycin for the
treatment of AML. This study is subject to appropriate future
filings with potential additional feedback from the FDA and their
foreign equivalents.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers. Moleculin is also engaged in the development of a
portfolio of antimetabolites, including WP1122 for the potential
treatment of pathogenic viruses, as well as certain cancer
indications.
For more information about the Company, please visit
www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin has attempted to identify
forward-looking statements by terminology including 'believes,'
'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,'
'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,'
'approximately' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transcript-from-moleculins-recent-virtual-acute-myeloid-leukemia-kol-event-now-available-302278559.html
SOURCE Moleculin Biotech, Inc.